Company Active LTD

Company profile

Frequasense Limited

Frequasense Limited is a UK company with status active founded in 2020 based in North East England.

CRN
12614398
Founded
2020
Age
6

Overview

Legal name
FREQUASENSE LIMITED
Region
North East England
Registered address
SUITE 5, SECOND FLOOR BULMAN HOUSE
REGENT CENTRE
NEWCASTLE UPON TYNE
NE3 3LS
Insolvency history
No

Latest accounts

Financial period: 1 Jun 2024 to 31 May 2025

ABRIDGEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
1

Company events

Reference milestones and recent Companies House filing stream events.

9 events
28 Feb
2027

Accounts due

Accounts Due

Next accounts due date

03 Jun
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

10 Apr
2026

Liquidation Voluntary Appointment Of Liquidator

Insolvency

600 | Transaction MzUxMjk2MjY4NmFkaXF6a2N4 | Paper/PDF filed

Published 10 Apr 2026 23:03

10 Apr
2026

Resolution

Resolution

RESOLUTIONS | Transaction WUVZUjNPUUphZGlxemtjeA | Paper/PDF filed

Published 10 Apr 2026 23:01

10 Apr
2026

Liquidation Voluntary Statement Of Affairs

Insolvency

LIQ02 | Transaction MzUxMjk2Mjg1OGFkaXF6a2N4 | Paper/PDF filed

Published 10 Apr 2026 22:59

10 Apr
2026

Change Registered Office Address Company With Date Old Address New Address

Address

AD01 | Transaction MzUxMjk2MzA4N2FkaXF6a2N4 | Paper/PDF filed

Published 10 Apr 2026 22:55

31 May
2025

Accounts filed

Accounts

Last accounts made up date

20 May
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

20 May
2020

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2022
Funded years
2022
Age at first award
1 years

Projects

2022 Collaborative R&D Lead participant

Development of a Novel Rapid Sepsis Point of Care Diagnostic Device

1 Feb 2022 to 31 Jul 2023

Awarded
£244,836
Total cost £349,766

More than 350,000 people suffer from sepsis in the UK annually, leading to 52,000 deaths. Rapid diagnosis is imperative to enable timely administration of interventional antibiotic treatment, however current methods are insufficient to empower clinicians to act within the critical first hour of admission. Early antibiotic therapy is vital to clinical outc...

Product types

Collaborative R&D